Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$21.24 USD
-0.26 (-1.21%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $21.13 -0.11 (-0.52%) 5:34 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DNTH 21.24 -0.26(-1.21%)
Will DNTH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DNTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNTH
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
DNTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock?
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
Other News for DNTH
Commit To Buy Dianthus Therapeutics At $12.50, Earn 26.6% Annualized Using Options
Dianthus (DNTH) Price Target Raised by Guggenheim Ahead of Key Trial
Dianthus price target raised by $8 at Guggenheim, here's why
Dianthus initiated with bullish view at William Blair, here's why
Dianthus Therapeutics (DNTH) Receives Outperform Rating by William Blair | DNTH Stock News